Latest Annual Reports
by Mike Gee
24 May 2026









































21Shares Dogecoin ETF
REVENUE
N/A
INCOME
N/A
EMPLOYEES
N/A
CUSTOMERS
N/A
21Shares Dogecoin ETF (TDOG) is a passive exchange-traded fund that seeks to track the price of Dogecoin (DOGE) using the CF Dogecoin‑Dollar US Settlement Price Index, holding DOGE through multiple custodians and charging a 0.50% sponsor fee.
View Company PageFiled: 2026-03-16
Alto Neuroscience, Inc.
REVENUE
N/A
INCOME
-$63,238,000
-2.94%
EMPLOYEES
68
CUSTOMERS
N/A
Clinical-stage biopharmaceutical company developing biomarker-guided therapies and companion diagnostics for neuropsychiatric disorders using EEG, cognitive, wearable, genetic data and machine learning to enable precision psychiatry.
View Company PageFiled: 2026-03-16
Assertio Holdings, Inc.
REVENUE
$118,713,000
-5.00%
INCOME
-$30,375,000
-40.75%
EMPLOYEES
53
CUSTOMERS
3
Assertio Holdings is a U.S.-focused specialty pharmaceutical company anchored by ROLVEDON, marketing oncology-supportive and analgesic products through distributor channels and relying on contract manufacturing.
View Company PageFiled: 2026-03-16
Aprea Therapeutics, Inc.
REVENUE
$285,759
-80.98%
INCOME
-$12,599,569
2.77%
EMPLOYEES
N/A
CUSTOMERS
N/A
Not explicitly described in the provided text; financials indicate a research-and-development-focused company (likely life sciences/biotech) primarily funded by grants and equity financings, with significant R&D and G&A expenses and recurring net losses.
View Company PageFiled: 2026-03-16
Ardent Health, Inc.
REVENUE
$6,324,339,000
6.01%
INCOME
$135,811,000
-35.43%
EMPLOYEES
25,200
CUSTOMERS
1,200,000
Ardent Health, Inc. operates a tech-enabled, consumer-focused platform of acute care hospitals and ambulatory services across multiple U.S. markets, primarily through joint ventures and a centralized Epic-based clinical and digital infrastructure.
View Company PageFiled: 2026-03-16
Atara Biotherapeutics, Inc.
REVENUE
$120,772,000
-6.33%
INCOME
$32,688,000
138.28%
EMPLOYEES
14
CUSTOMERS
N/A
Atara Biotherapeutics is a biopharmaceutical company developing off-the-shelf, allogeneic EBV‑sensitized T‑cell therapies (marketed as Ebvallo/tab-cel in Europe/UK/Switzerland) for EBV-driven cancers and autoimmune diseases, leveraging strategic partnerships for commercialization and manufacturing.
View Company PageFiled: 2026-03-16
AGENUS INC
REVENUE
$108,588,000
7.54%
INCOME
-$3,083,000
98.67%
EMPLOYEES
81
CUSTOMERS
1,200
Agenus Inc. is a clinical‑stage immuno‑oncology biotechnology company focused on developing botensilimab (anti‑CTLA‑4) and balstilimab (anti‑PD‑1) — primarily as the BOT+BAL combination in colorectal cancer — alongside discovery platforms, partnerships, and manufacturing collaborations.
View Company PageFiled: 2026-03-16
Apartment Income REIT, L.P.
REVENUE
$793,174,000
-0.93%
INCOME
$214,742,000
160.35%
EMPLOYEES
810
CUSTOMERS
25,743
AIR Operating Partnership is a Blackstone-affiliated owner and operator of 70 stabilized, market-rate apartment communities (25,743 homes) across major U.S. markets that uses a centralized operating platform (AIR Edge) to optimize property operations and services.
View Company PageFiled: 2026-03-13
Alto Ingredients, Inc.
REVENUE
$917,927,000
-4.90%
INCOME
$13,338,000
122.61%
EMPLOYEES
390
CUSTOMERS
82
U.S. producer and distributor of specialty alcohols, renewable fuels and essential ingredients with production facilities in Pekin, Illinois; Boardman, Oregon; and Burley, Idaho, serving domestic and international customers across multiple end markets.
View Company PageFiled: 2026-03-13
BAR HARBOR BANKSHARES
REVENUE
$168,934,000
12.08%
INCOME
$36,919,000
-15.21%
EMPLOYEES
530
CUSTOMERS
144,000
Bar Harbor Bankshares is a regional community bank holding company focused on Northern New England that provides retail and commercial banking, wealth management, fiduciary and brokerage services through Bar Harbor Bank & Trust and its subsidiaries.
View Company PageFiled: 2026-03-13
Apollo Origination II (UL) Capital Trust
REVENUE
$47,298,000
INCOME
$43,999,000
EMPLOYEES
N/A
CUSTOMERS
N/A
Apollo Origination II (UL) Capital Trust is a newly organized, externally managed, non-diversified closed-end Business Development Company and Regulated Investment Company (Delaware statutory trust) that focuses on originating secured private credit—primarily loans to large private U.S. and select non-U.S. corporate borrowers—managed and administered by Apollo Credit Management, LLC.
View Company PageFiled: 2026-03-13
Apollo Origination II (Levered) Capital Trust
REVENUE
$107,992,000
INCOME
$58,205,000
EMPLOYEES
N/A
CUSTOMERS
N/A
Apollo Origination II (Levered) Capital Trust is a Delaware statutory trust organized as a non-diversified, closed-end business development company and regulated investment company that primarily originates and invests in private senior secured loans to large U.S. borrowers using leverage and Apollo's platform.
View Company Page